drugset / Trial / NCT07358377
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.
Timeline
- Start
- 2026-05-15
- Primary completion
- 2027-04-10
- Completion
- 2027-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-6209 | Small molecule | 100 mg | — |
| Background | Fulvestrant | Small molecule | — | — |